OKYO PHARMA LTD OKYO

US Healthcare Biological Products, (No Diagnostic Substances)
$1.57
+4.7%
52w: $1.49 – $3.27

Latest 13F among current holders filed 1 month ago (May 15, 2026)

Price — last 12 months

research preview data
1.492.383.27
Jun 20, 2025 Jul 2, 2026
Institutional holders
12
+2 QoQ
13F value
$10.3M
+796.5% QoQ
Smart-money holders
2
signal tier ≥ 2
New smart buyers
1
Q1 2026

Institutional value by quarter

$1.4M
Q1 2024
$1.2M
Q2 2024
$1.0M
Q3 2024
$1.2M
Q4 2024
$2.6M
Q1 2025
$1.5M
Q2 2025
$5.1M
Q3 2025
$1.1M
Q4 2025
$10.3M
Q1 2026

Number of holders

7
Q1 2024
8
Q2 2024
7
Q3 2024
8
Q4 2024
8
Q1 2025
6
Q2 2025
8
Q3 2025
10
Q4 2025
12
Q1 2026

Who owns OKYO?

Q1 2026 filings
FundTypeSharesValue% of fundChange
Woodline Partners LP Other3.7M$5.9M0.0%New
Maven Securities LTD Quant stat arb1.2M$1.9M0.1%New
Stonepine Capital Management, LLC ★2Fundamental concentrated850.0K$1.4M1.2%New
Balyasny Asset Management L.P. Multistrat pod584.8K$942K0.0%New
UBS Group AG Bank broker59.8K$96K0.0%+2651.4%
XTX Topco Ltd Market maker37.7K$61K0.0%+113.8%
Cerity Partners LLC Diversified mechanical12.8K$21K0.0%Held
GEODE CAPITAL MANAGEMENT, LLC Index provider12.1K$19K0.0%Held
Dauntless Investment Group, LLC ★2Fundamental concentrated3.8K$6K0.0%-99.2%
EFG International AG Other923$1K0.0%Held
OSAIC HOLDINGS, INC. Wealth advisor152$2440.0%Held
MORGAN STANLEY Bank broker10$160.0%Held

Exits are not a bearish signal: our backtest shows stocks specialists exit keep outperforming for 3+ quarters — selling usually means profit-taking, not a forecast.